Substitution of D-Arginine at Position 11 of α-RgIA Potently Inhibits α7 Nicotinic Acetylcholine Receptor

Conotoxins are a class of disulfide-rich peptides found in the venom of cone snails, which have attracted considerable attention in recent years due to their potent activity on ion channels and potential for therapeutics. Among them, α-conotoxin RgIA, a 13-residue peptide, has shown great promise as a potent inhibitor of α9α10 nAChRs for pain management. In this study, we investigated the effect of substituting the naturally occurring L-type arginine at position 11 of the RgIA sequence with its D-type amino acid. Our results indicate that this substitution abrogated the ability of RgIA to block α9α10 nAChRs, but instead endowed the peptide with the ability to block α7 nAChR activity. Structural analyses revealed that this substitution induced significant alteration of the secondary structure of RgIA[11r], which consequently affected its activity. Our findings underscore the potential of D-type amino acid substitution as a promising strategy for designing novel conotoxin-based ligands targeting different types of nAChRs.


Introduction
Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop ligand-gated ion channel superfamily which play crucial roles in rapid synaptic transmission and have been implicated in a range of nervous system diseases. To date, sixteen nAChR subunits (α1-α7, α9, α10, β1-β4, γ, δ and ε) have been identified in mammalian species. These subunits combine into hetero-or homo-pentamers to form nAChRs with different pharmacological and kinetic properties, as well as their localization [1]. The homomeric α7 nAChR has been intensely studied since its original discovery [2]. In the central nervous system, α7 nAChR is mainly distributed in the hippocampus and the cerebral cortex, regions associated with learning and memory mechanisms. Major human pathologies such as epilepsy, myasthenic syndromes, schizophrenia, Parkinson's and Alzheimer's diseases result from a dysfunction of α7 nAChR. Moreover, α7 nAChR is also located on the surface of macrophages, which plays a vital role in the cholinergic anti-inflammatory pathway. Therefore, ligands specifically designed to target the α7 receptor have the potential to be developed as drugs for the treatment of these diseases [3].
Conotoxins are a class of disulfide-rich peptides that are present in the venom of cone snails. Conotoxins have been shown to selectively and effectively modulate the function of ion channels and receptors in the nervous system [4]. Some of these peptides have been utilized as pharmacological probes, while others have been developed as potential drug leads. Notably, ω-conotoxin MVIIA, which is known as Ziconotide or Prialt, is a wellknown example of a conotoxin-derived drug that targets the calcium channel CaV 2.2 and is approved for the treatment of neuropathic pain [5,6]. Among the families of conotoxins, α-conotoxins are distinguished by their selective antagonism against different subtypes of nAChRs, rendering them a significant source for the development of nAChR ligands. The α-conotoxin family consists of peptides comprising 12-19 amino acids, which typically possess an amidated C-terminus, wherein the hydroxyl group of the carboxyl group is replaced with an amide. These peptides contain four cysteines (CysI-CysIII, CysII-CysIV), forming two pairs of disulfide bonds. Based on the number of amino acids between the cysteines (m/n), they can be categorized into various subtypes. In general, 3/5 (m/n) α-conotoxins act as selective antagonists of muscle type, whereas 4/7, 4/4 and 4/3 αconotoxins selectively antagonize non-muscle type nAChRs. The pharmacological effects of these peptides have been extensively investigated. Studies have demonstrated that the first loop harbors a conserved hydrophobic region, which determines its binding, whereas the second loop comprises a more variable region that confers selectivity. In vivo and in vitro, some of these peptides display therapeutic potential. Notably, some conotoxins have been found to inhibit the α7 receptor with high affinity [4,[7][8][9].
α-RgIA was discovered through cDNA sequencing of the venom gland of Conus regius [10]. The sequence and structure of this peptide are depicted in Figure 1. It belongs to the relatively uncommon class of α4/3-conotoxins, featuring four cysteines that form two pairs of disulfide bonds in the sequence and a high abundance of arginine residues. RgIA and its derivatives selectively and potently inhibit heterologous α9α10 nAChR, which was found to be a neuropathic pain target. RgIA4, an analogue of RgIA, has garnered attention due to its high affinity towards human α9α10 nAChRs [11]. The University of Utah has licensed RgIA4 to Kineta, under the designation KCP-400, for preclinical development [12]. However, the high arginine content of RgIA has raised concerns regarding its stability and in vivo bioavailability. To address this issue, we have employed a strategy of substituting amino acids with their D-form counterparts, leading to improved stability of RgIA while preserving its biological activity [13]. In this study, we have identified that one of the mutants containing a D-type amino acid substitution, RgIA[11r] (Figure 1), effectively inhibits the α7 nAChR and significantly decreases the potency at the α9α10 nAChR. These results suggest that D-type amino acid substitution not only enhances the stability of conotoxins but also enables the design of peptide ligands that can target other nAChR subtypes.
Mar. Drugs 2023, 21, x FOR PEER REVIEW 2 of 13 known example of a conotoxin-derived drug that targets the calcium channel CaV2.2 and is approved for the treatment of neuropathic pain [5,6]. Among the families of conotoxins, α-conotoxins are distinguished by their selective antagonism against different subtypes of nAChRs, rendering them a significant source for the development of nAChR ligands. The α-conotoxin family consists of peptides comprising 12-19 amino acids, which typically possess an amidated C-terminus, wherein the hydroxyl group of the carboxyl group is replaced with an amide. These peptides contain four cysteines (CysI-CysIII, CysII-CysIV), forming two pairs of disulfide bonds. Based on the number of amino acids between the cysteines (m/n), they can be categorized into various subtypes. In general, 3/5 (m/n) αconotoxins act as selective antagonists of muscle type, whereas 4/7, 4/4 and 4/3 α-conotoxins selectively antagonize non-muscle type nAChRs. The pharmacological effects of these peptides have been extensively investigated. Studies have demonstrated that the first loop harbors a conserved hydrophobic region, which determines its binding, whereas the second loop comprises a more variable region that confers selectivity. In vivo and in vitro, some of these peptides display therapeutic potential. Notably, some conotoxins have been found to inhibit the α7 receptor with high affinity [4,[7][8][9]. α-RgIA was discovered through cDNA sequencing of the venom gland of Conus regius [10]. The sequence and structure of this peptide are depicted in Figure 1. It belongs to the relatively uncommon class of α4/3-conotoxins, featuring four cysteines that form two pairs of disulfide bonds in the sequence and a high abundance of arginine residues. RgIA and its derivatives selectively and potently inhibit heterologous α9α10 nAChR, which was found to be a neuropathic pain target. RgIA4, an analogue of RgIA, has garnered attention due to its high affinity towards human α9α10 nAChRs [11]. The University of Utah has licensed RgIA4 to Kineta, under the designation KCP-400, for preclinical development [12]. However, the high arginine content of RgIA has raised concerns regarding its stability and in vivo bioavailability. To address this issue, we have employed a strategy of substituting amino acids with their D-form counterparts, leading to improved stability of RgIA while preserving its biological activity [13]. In this study, we have identified that one of the mutants containing a D-type amino acid substitution, RgIA[11r] (Figure 1), effectively inhibits the α7 nAChR and significantly decreases the potency at the α9α10 nA-ChR. These results suggest that D-type amino acid substitution not only enhances the stability of conotoxins but also enables the design of peptide ligands that can target other nAChR subtypes.

Synthesis of RgIA and RgIA[11r]
This study employed the Fmoc solid-phase synthesis method to synthesize linear peptides of RgIA and RgIA [11r]. To produce RgIA[11r], the L-Arg residue at position 11 was substituted with D-Arg, yielding two peptides with identical theoretical molecular

Synthesis of RgIA and RgIA[11r]
This study employed the Fmoc solid-phase synthesis method to synthesize linear peptides of RgIA and RgIA [11r]. To produce RgIA[11r], the L-Arg residue at position 11 was substituted with D-Arg, yielding two peptides with identical theoretical molecular weights. To synthesize the folded peptides, a directed two-step folding approach was utilized. The Cys pairs were orthogonally protected using S-trityl (S-Trt) and acid-stable S-acetamidomethyl (S-Acm) groups. Selective removal of the S-trityl groups was achieved through cleavage from the resin, allowing the deprotected Cys residues to be oxidized with 20 mM potassium ferricyanide and 0.1 M Tris-HCl. Semi-preparative reversed phase-highperformance liquid chromatography (RP-HPLC) purification of the monocyclic peptide was then carried out, followed by treatment with iodine, resulting in the formation of the second disulfide bond between Cys3-Cys12. The molecular mass and purities of all peptides were validated with electrospray ionization-mass spectrometry (ESI-MS) and analytical RP-UPLC, respectively, as illustrated in Figure 2. The retention time of RgIA was 1.798 min, whereas that of RgIA[11r] was 1.717 min, indicating that RgIA[11r] was more hydrophilic when position 11 was substituted with D-Arg. The molecular weight of RgIA was determined to be 1571. 13  weights. To synthesize the folded peptides, a directed two-step folding approach w lized. The Cys pairs were orthogonally protected using S-trityl (S-Trt) and acid-s acetamidomethyl (S-Acm) groups. Selective removal of the S-trityl groups was a through cleavage from the resin, allowing the deprotected Cys residues to be o with 20 mM potassium ferricyanide and 0.1 M Tris-HCl. Semi-preparative r phase-high-performance liquid chromatography (RP-HPLC) purification of the m clic peptide was then carried out, followed by treatment with iodine, resulting in mation of the second disulfide bond between Cys3-Cys12. The molecular mass an ties of all peptides were validated with electrospray ionization-mass spectromet MS) and analytical RP-UPLC, respectively, as illustrated in Figure 2. The retention RgIA was 1.798 min, whereas that of RgIA[11r] was 1.717 min, indicating that Rg was more hydrophilic when position 11 was substituted with D-Arg. The mo weight of RgIA was determined to be 1571. 13 Da, and that of RgIA[11r] was 1570 consistent with the theoretical molecular weight. Our study demonstrates the suc synthesis and purification of folded RgIA and RgIA[11r] peptides using a direct step folding approach.

Potency of RgIA and RgIA[11r] at the Different Types of nAChRs
We conducted a comprehensive assessment of RgIA[11r]'s inhibitory activity (10 µM) against various types of nAChRs, namely rat (r) α3β2, α4β4, α3β4, α6/α3β4, α4β2, α2β4, α7 and α9α10; and mouse (m) α1β1δγ, heterologously expressed in Xenopus laveis oocytes, using the two-electrode voltage clamp recording method. The results are presented in Figure 3. At α7 nAChRs, wild-type RgIA (10 µM) demonstrated a 60% inhibitory effect on acetylcholine (ACh)-evoked currents. In contrast, RgIA[11r] displayed potent activity at α7 receptors, inhibiting approximately 95% of the ACh currents. Inhibition of other receptors was below 50% ( Figure 3C). Remarkably, previous studies have reported that RgIA inhibits α9α10 at nanomolar levels [13]. However, surprisingly, 10 µM RgIA[11r] only inhibited 60% of α9α10 ACh currents.  The effective inhibition of hα7 nAChRs by RgIA at 10 µM having been e we proceeded to determine the concentration response relationships of RgIA[11r] at α7 and α9α10 nAChRs ( Figure 4). The corresponding half-maxi tory concentration (IC50) values for their inhibition of ACh-evoked currents m rat α7 and α9α10 nAChRs are summarized in Table 1. Wild-type RgIA display antagonistic activity against rα9α10 receptors, exhibiting an IC50 value of 2.6 weak activity against rα7, with an IC50 of only 5313 nM, a result similar to tho previously [10]. In the present study, the replacement of the L-type arginine at with D-arginine resulted in the reversal of the activity of the mutant RgIA[11r] showed inhibitory activity against rα7 with an IC50 of 163 nM, while it exhibite minimal (IC50 = 15,820 nM) against rα9α10. Consequently, we proceeded to det inhibitory activity of RgIA and RgIA[11r] against human α9α10 and α7, and are presented in Figure 4 and Table 1. Wild-type RgIA displayed weak activ both human-derived α9α10 and α7 receptors, exhibiting IC50 values of 1398 an respectively. Surprisingly, RgIA[11r] showed no detectable activity against h still maintained a potency of 463 nM against hα7. Overall, compared to the RgIA, RgIA[11r] demonstrated a significant enhancement in activity towards man α7 nAChRs, with an increase of 32.6-fold and 9.96-fold, respectively. H activity towards α9α10 nAChRs was nearly completely lost. These findings s the conformation of the arginine residue at position 11 of RgIA was altered, w cant effects on its inhibition at α7 and α9α10 nAChRs. The effective inhibition of hα7 nAChRs by RgIA at 10 µM having been established, we proceeded to determine the concentration response relationships of RgIA and RgIA[11r] at α7 and α9α10 nAChRs ( Figure 4). The corresponding half-maximal inhibitory concentration (IC 50 ) values for their inhibition of ACh-evoked currents mediated by rat α7 and α9α10 nAChRs are summarized in Table 1. Wild-type RgIA displayed a robust antagonistic activity against rα9α10 receptors, exhibiting an IC 50 value of 2.6 nM, but a weak activity against rα7, with an IC 50 of only 5313 nM, a result similar to those obtained previously [10]. In the present study, the replacement of the L-type arginine at position 11 with D-arginine resulted in the reversal of the activity of the mutant RgIA[11r]. RgIA[11r] showed inhibitory activity against rα7 with an IC 50 of 163 nM, while it exhibited relatively minimal (IC 50 = 15,820 nM) against rα9α10. Consequently, we proceeded to determine the inhibitory activity of RgIA and RgIA[11r] against human α9α10 and α7, and the results are presented in Figure 4 and Table 1. Wild-type RgIA displayed weak activity against both human-derived α9α10 and α7 receptors, exhibiting IC 50 values of 1398 and 4608 nM, respectively. Surprisingly, RgIA[11r] showed no detectable activity against hα9α10, but still maintained a potency of 463 nM against hα7. Overall, compared to the wild-type RgIA, RgIA[11r] demonstrated a significant enhancement in activity towards rat and human α7 nAChRs, with an increase of 32.6-fold and 9.96-fold, respectively. However, its activity towards α9α10 nAChRs was nearly completely lost. These findings suggest that the conformation of the arginine residue at position 11 of RgIA was altered, with significant effects on its inhibition at α7 and α9α10 nAChRs.

Circular Dichroism (CD) Spectra of RgIA and RgIA[11r]
In this study, we compared the secondary structure conformation of RgIA with th of RgIA[11r] using CD spectroscopic analysis ( Figure 5). The 3D structure of RgIA shown in Figure 1B, with a type I β-turn at its N-terminus from Cys2 to Asp5, while lo II from Tyr10-Cys12 is less well-defined. Our results show that when L-Arg residue position 11 was replaced with a D-Arg residue, its negative absorption peak at 208 n and its positive absorption peak at 222 nm were enhanced. This suggests that there m be a tendency for the formation of α-helix at Loop II of RgIA[11r], which indicates th the structure of RgIA is altered when the arginine of 11 is replaced by D-type amino ac This result is significantly different from our previous study, where the replacement Arg-13 by D-Arg had less effect on the structure of RgIA [13].

Circular Dichroism (CD) Spectra of RgIA and RgIA[11r]
In this study, we compared the secondary structure conformation of RgIA with that of RgIA[11r] using CD spectroscopic analysis ( Figure 5). The 3D structure of RgIA is shown in Figure 1B, with a type I β-turn at its N-terminus from Cys2 to Asp5, while loop II from Tyr10-Cys12 is less well-defined. Our results show that when L-Arg residue at position 11 was replaced with a D-Arg residue, its negative absorption peak at 208 nm and its positive absorption peak at 222 nm were enhanced. This suggests that there may be a tendency for the formation of α-helix at Loop II of RgIA[11r], which indicates that the structure of RgIA is altered when the arginine of 11 is replaced by D-type amino acid. This result is significantly different from our previous study, where the replacement of Arg-13 by D-Arg had less effect on the structure of RgIA [13].

Serum Stability of RgIA and RgIA[11r]
We assessed the stability of wild-type RgIA and its 11-position D-amino a tution mutant, RgIA[11r], in human serum. The experimental results, as depic ure 6, indicated poor stability for both peptides, with complete degradation within 30 min. This suggests that the substitution of individual amino acids with acids did not significantly enhance peptide stability. Our previous research h strated a notable improvement in stability when all arginine residues were rep D-amino acids [13].

Molecular Docking (MD) Demonstrates Altered Potency between RgIA[11r] and ChRs
To further analyze the molecular mechanism underlying the targeting of t ChRs by RgIA[11r], we performed separate molecular docking studies between RgIA[11r] with the human α7 nAChRs. The docking results, as illustrated in revealed that the 11-position D-amino acid in RgIA[11r] formed a hydrogen residue 139-Gln in the extracellular region of the α7 nAChRs, while RgIA itse exhibit any interactions with the α7 nAChRs. The docking scores indicated a val

Serum Stability of RgIA and RgIA[11r]
We assessed the stability of wild-type RgIA and its 11-position D-amino acid substitution mutant, RgIA[11r], in human serum. The experimental results, as depicted in Figure 6, indicated poor stability for both peptides, with complete degradation observed within 30 min. This suggests that the substitution of individual amino acids with D-amino acids did not significantly enhance peptide stability. Our previous research has demonstrated a notable improvement in stability when all arginine residues were replaced with D-amino acids [13].
Mar. Drugs 2023, 21, x FOR PEER REVIEW

Serum Stability of RgIA and RgIA[11r]
We assessed the stability of wild-type RgIA and its 11-position D-amino acid tution mutant, RgIA[11r], in human serum. The experimental results, as depicted ure 6, indicated poor stability for both peptides, with complete degradation ob within 30 min. This suggests that the substitution of individual amino acids with D acids did not significantly enhance peptide stability. Our previous research has d strated a notable improvement in stability when all arginine residues were replace D-amino acids [13].

Molecular Docking (MD) Demonstrates Altered Potency between RgIA[11r] and α7 ChRs
To further analyze the molecular mechanism underlying the targeting of the ChRs by RgIA

Molecular Docking (MD) Demonstrates Altered Potency between RgIA[11r] and α7 nAChRs
To further analyze the molecular mechanism underlying the targeting of the α7 nAChRs by RgIA[11r], we performed separate molecular docking studies between RgIA and RgIA[11r] with the human α7 nAChRs. The docking results, as illustrated in Figure 7

Discussion
Initially, we used D-alanine scanning to study the key amino acid residues of RgIA and found that, except for arginine at position 13, the activity was greatly reduced after replacing the amino acids at other positions with D-amino acids [13]. Based on the synthesized D-type RgIA derivatives, we tested the activity of other subtypes of nAChRs and were surprised to find that RgIA[11r] had strong inhibition activity against the α7 nA-ChRs. Building on this finding, we discovered that RgIA[11r] had strong blocking activity against human and murine α7 nAChRs.
Previous research has indicated that homomeric α7 nAChRs play a significant role in regulating neuropsychiatric and neurological disorders, as well as the inflammatory response of immune cells [15,16]. Given their potential as targets for treating inflammatory and neuropathic pain, the crucial physiological functions of α7 nAChRs have sparked considerable interest in developing drugs that target these receptors. Agonists or antagonists of α7 have emerged as promising candidates for drug development to treat α7-related diseases [2]. Numerous α-conotoxins and their analogues that can inhibit α7 nA-ChRs have been discovered (Table 2). Among these, α4/3-conotoxins ImI and ImII have been extensively studied and found to block various nAChR subtypes. In the case of α7 nAChRs, different research groups have reported varying potencies [17,18]. Multiple α4/7-conotoxins, such as GID, OmIA and PeIA, inhibiting α7 nAChRs with high potency, have demonstrated blocking effects on different types of nAChRs, with particularly strong activity against α3β2 nAChRs. The ArIB mutant ArIB [V11L, V16A] has potent activity targeting α7 nAChRs, with IC50s as low as picomolar levels, and a certain inhibitory effect at rα6/α3β2β3 nAChRs. In our laboratory, the α4/4-conotoxin [Q1G,ΔR14]LvIB had strong activity at rat α7 nAChRs, but low activity against human receptors [19]. In this study, RgIA[11r] exhibited an IC50 of 463 nM and 163 nM at human and rat α7 nAChRs, respectively. In comparison to other α-conotoxins acting on α7 nAChRs, RgIA[11r], although not the most potent, displayed relatively good selectivity for the α7 subtype with negligible inhibition at other nAChR subtypes. It is known that certain conotoxin peptides exhibit high activity against murine receptors but weak activity against human receptors, thereby limiting their clinical potential. The present investigation demonstrated that RgIA[11r] also exhibited higher activity against hα7 nAChRs, and therefore holds significant medicinal value. It is plausible that this peptide may serve as a framework for designing more potent peptide ligands targeting hα7 nAChRs.

Discussion
Initially, we used D-alanine scanning to study the key amino acid residues of RgIA and found that, except for arginine at position 13, the activity was greatly reduced after replacing the amino acids at other positions with D-amino acids [13]. Based on the synthesized D-type RgIA derivatives, we tested the activity of other subtypes of nAChRs and were surprised to find that RgIA[11r] had strong inhibition activity against the α7 nAChRs. Building on this finding, we discovered that RgIA[11r] had strong blocking activity against human and murine α7 nAChRs.
Previous research has indicated that homomeric α7 nAChRs play a significant role in regulating neuropsychiatric and neurological disorders, as well as the inflammatory response of immune cells [15,16]. Given their potential as targets for treating inflammatory and neuropathic pain, the crucial physiological functions of α7 nAChRs have sparked considerable interest in developing drugs that target these receptors. Agonists or antagonists of α7 have emerged as promising candidates for drug development to treat α7-related diseases [2]. Numerous α-conotoxins and their analogues that can inhibit α7 nAChRs have been discovered (Table 2). Among these, α4/3-conotoxins ImI and ImII have been extensively studied and found to block various nAChR subtypes. In the case of α7 nAChRs, different research groups have reported varying potencies [17,18]. Multiple α4/7-conotoxins, such as GID, OmIA and PeIA, inhibiting α7 nAChRs with high potency, have demonstrated blocking effects on different types of nAChRs, with particularly strong activity against α3β2 nAChRs. The ArIB mutant ArIB [V11L, V16A] has potent activity targeting α7 nAChRs, with IC 50 s as low as picomolar levels, and a certain inhibitory effect at rα6/α3β2β3 nAChRs. In our laboratory, the α4/4-conotoxin [Q1G,∆R14]LvIB had strong activity at rat α7 nAChRs, but low activity against human receptors [19]. In this study, RgIA[11r] exhibited an IC 50 of 463 nM and 163 nM at human and rat α7 nAChRs, respectively. In comparison to other α-conotoxins acting on α7 nAChRs, RgIA[11r], although not the most potent, displayed relatively good selectivity for the α7 subtype with negligible inhibition at other nAChR subtypes. It is known that certain conotoxin peptides exhibit high activity against murine receptors but weak activity against human receptors, thereby limiting their clinical potential. The present investigation demonstrated that RgIA[11r] also exhibited higher activity against hα7 nAChRs, and therefore holds significant medicinal value. It is plausible that this peptide may serve as a framework for designing more potent peptide ligands targeting hα7 nAChRs. Amino acids exist as two enantiomers: L and D, except for glycine, which lacks a chiral center. Although the D-amino acid (D-AA) enantiomer of α-amino acids was once considered unimportant in biological systems, it has garnered significant interest among researchers due to its ability to improve protein stability. One of the major challenges in peptide development is their susceptibility to degradation by proteases, resulting in a short half-life in the human intestine, plasma and cells. Therefore, enhancing peptide stability and bioavailability is crucial to improve their medicinal value. To address this challenge, analogues such as cyclodextrin (D)-amino-acid-engineered analogues have been designed to prolong their half-life in humans [30]. It is well recognized that the conversion of one enantiomer to another in a biological system can cause significant structural changes in peptides or proteins, which can affect their function and biological activity. The inversion of stereochemistry at the chiral center and the corresponding conformational preferences of D-AAs to their L-counterparts often lead to instability of the secondary structure when D-AAs are incorporated into L-peptides or proteins. However, it has been observed that peptides with α-helix, long β-strand and long loop structures are generally less sensitive to substitution with D-AAs than short β-strands [31]. In this study, we observed changes in the structure when arginine at the 11th position was replaced with the D-form, as determined by CD spectra. Although the amino acid sequence of conotoxin peptides is short, their spatial structure is compact, and the amino acids located in the loop formed by cysteine residues have a significant impact on their activity and selectivity. In the present investigation, the substitution of the 11th arginine residue with a D-configured amino acid resulted in the loss of the peptide's original activity and a shift towards antagonizing α7 nAChRs. We utilized molecular docking to elucidate the molecular mechanism of interaction between the mutant RgIA[11r] and hα7 nAChRs. Our findings reveal the formation of new hydrogen bonds. However, our previous studies have demonstrated that when other residues except for Arg-11 in RgIA were substituted with D-configuration, no activity towards hα7 nAChRs was observed [13]. This suggests that the substitution of peptides with D-configured amino acids requires careful consideration and further investigation. Nevertheless, this study provides a direction for the subsequent design highly selective and active conotoxins.

Materials
Clones of rat (r)α2, α3, α4, α7 and β2, β3 and β4, as well as mouse (m) α1, β1, δ and ε cDNAs were generously provided by S. Heinemann (Salk Institute, La Jolla, CA, USA). It is worth noting that that the rα6 subunit is difficult to express in vitro, so we constructed the rα6/α3 chimeric subunit instead, which consisted of the N-terminal extracellular ligand-binding domain of the rα6 subunit and the remainder as the rα3 subunit segment. The rα6/α3 chimera clone was generously provided by J. E. Garrett (Cognetix, Inc., Salt Lake City, UT, USA). Clones of rα9 and rα10 were kindly provided by A.B. Elgoyen

RgIA and RgIA[11r] Synthesis
The synthesis of conopeptides was accomplished on a 0.05 mmol scale using a Liberty Blue automated peptide synthesizer (CEM, Charlotte, NC, USA), applying standard solidphase Fmoc (9-fluorenylmethyloxycarbonyl) protocols using Fmoc-Arg(Pbf) Wang resin (0.49 mmol/g load). During the assembly process, Cys3 and Cys12 were integrated into the peptide chain with Acm side chain protection to aid in regioselective disulfide formation, while Cys2 and Cys8 were protected with Trt side chain. The peptides were subsequently cleaved from the resin with trifluoroacetic acid (TFA) in the presence of tri-isopropylsilane (TIPS) and water (9:0.5:0.5 (v/v/v) TFA:TIPS:water) at room temperature for 2 h, resulting in simultaneously removing the side-chain-protecting groups, except for cysteines with Acm. Then, the cleavage mixture was filtered and precipitated with 40 mL of cold ether. The crude peptide was then precipitated by centrifugation at 9000× g for 15 min and washed twice with approximately 40 mL of cold ether, air-dried and then dissolved in 5 mL 0.05% TFA, 50% acetonitrile containing and vacuum lyophilized. The crude peptides were solubilized with 50 mL of HPLC buffer B, diluted to 10-fold volume prior to purification by Semi-preparative RP-HPLC, using a preparative XBridge Peptide BEH C18 column eluted with a linear gradient ranging from 2 to 50% buffer B in 48 min at a flow rate 12 mL/min. The buffers were 0.05% (v/v) TFA in water (buffer A) and 0.05% TFA (v/v) in 60% aqueous acetonitrile (v/v) (buffer B). The eluent was monitored by measuring absorbance at 214 nm. The purity of the peptide was assessed by ACQUITY UPLC BEH C18 column RP-HPLC (buffer A: 0.05% (v/v) TFA in water; buffer B: 90% aqueous acetonitrile (v/v)) using the same gradient as described above with a flow rate 0.5 mL/min. The peptide solution with higher purity was collected, put into a −80 • C ultra-low temperature refrigerator overnight, and then frozen into powder by vacuum freeze-dryer. The linear peptides were then dissolved in 0.1 M Tris-HCl buffer containing 20 mM potassium ferricyanide to facilitate the formation of the first disulfide. The second disulfide bond was formed through iodine oxidation, as previously described [32]. The purity of RgIA and RgIA[11r] was confirmed using analytical RP-UPLC as described for the linear peptide after oxidative folding. Finally, electrospray mass spectrometry was utilized to confirm the molecular weight of the synthetic peptides. The purity for all fully folded peptides was ≥95% and was determined using analytical RP-UPLC.

cRNA Preparation and Injection into Xenopus laevis Oocytes
The plasmids containing the human, rat and mouse nAChR subunits were linearized using an appropriate restriction enzyme (TaKaRa, Kyoto, Japan). Capped RNA was synthesized in vitro for these subunits using the T7 mMessage mMachine Transcription Kit (Ambion, Austin, TX, USA) and purified using the MEGA clearTM Transcription clean-up Kit (Invitrogen; Thermo Fisher Scientific, Inc., Austin, TX, USA). The concentration of each cRNA was determined at 260 nm using a Smart SpecTM plus Spectrophotometer (Bio-Rad, Hercules, CA, USA). To produce 200-500 ng/µL of cRNA for each subunit, the various subunit cRNAs were mixed with ratio 1:1, and 50 nL aliquots were injected into the cytoplasm of the oocytes using a Drummond microdispenser (Drummond Scientific, Broomall, PA, USA). The oocytes were then incubated at 18 • C in ND-96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 and 5 mM HEPES, pH 7.4) containing 10 mg/L penicillin, 10 mg/L streptomycin and 100 mg/L gentamicin.

Electrophysiological Recordings
As previously reported [33], Xenopus oocytes were analyzed using the two-electrode voltage-clamp method 3-5 days after injection. The oocytes were recorded using an Axoclamp 900A amplifier (Molecular Devices Corp., Sunnyvale, CA, USA) and the Clampfit 10.2 software (Molecular Devices Corp., Sunnyvale, CA, USA). The oocyte chamber was a cylindrical groove with a volume of approximately 50 mL, which was perfused with ND-96 buffer containing 0.1 mg/mL BSA at a flow rate of 2-4 mL/min under gravity. During the recording, the oocytes were held at a voltage of −70 mV and stimulated with a one-second pulse of 200 µM ACh every minute to stimulate α7 nAChRs. After establishing a stable baseline, the flow of buffer was stopped, and the oocytes were pre-incubated for 5 min with pure ND-96 or ND-96 containing different concentrations of conotoxins before the recovery of the ACh pulse.

Statistical Analysis
The percentage of response to conotoxin was obtained by dividing the toxin response by the pre-intoxication baseline value. Dose-response data were analyzed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA) and fitted with the formula: percentage response = 100/(1 − ([toxin]/IC 50 )ˆnH), where nH is the Hill coefficient. Each data point on the dose-response curve represents the mean ± S.E. of at least three oocytes. The IC 50 values with 95% confidence interval were determined by nonlinear regression analysis with GraphPad Prism software.

Circular Dichroism (CD) Spectroscopy
CD spectra of RgIA and RgIA[11r] in aqueous solution were obtained using a Chirascan CD spectrometer (Applied Photophysics, Leatherhead, UK). The CD spectra were recorded at room temperature under a constant nitrogen flush. The peptides were dissolved in water at a concentration of 200 µM and measurements were performed in a 1 mm quartz cuvette. Peptide spectral data were recorded in the far UV range (190-260 nm) with a step size and bandwidth of 1 nm. The spectra were obtained from the average of five measure-ments after subtraction of the background signal, which was also averaged. The spectra were expressed in units of molar ellipticity (θ) using Applied Photophysics Chirascan and Photophysics Chirascan software (Applied Photophysics, Leatherhead, U.K.).

Serum Stability Assay
Serum stability assays were conducted employing human serum sourced from male AB plasma (Sigma-Aldrich, Darmstadt, Germany) following a modified protocol as previously described by Andrew et al. [34]. Human serum was subjected to an additional incubation period of 15 min at 37 • C prior to the commencement of the assay. Triplicate samples of peptides were dissolved in Milli-Q water at a concentration of 1 mg/mL and subsequently diluted with serum to a concentration of 0.1 mg/mL. The samples were then incubated at 37 • C, and 20 µL aliquots were collected at specific time intervals of 0, 1, 5, 10, 15, 30, 60, 120, 240 and 480 min. Each sample underwent denaturation by adding an equal volume of 6 M urea and incubating at 4 • C for 10 min. Following denaturation, precipitation was achieved by adding an equal volume of 20% trichloroacetic acid at 4 • C for 10 min. The samples were subsequently centrifuged at 14,000 rpm for 10 min, and 10 µL of the resulting supernatant was analyzed using RP-UPLC. Each sample was subjected to repeated analysis twice. The remaining percentage of the peptide was determined by comparing the areas under the curve to the samples measured at the initial time point (0 min).

Docking
The glide docking method was employed to construct the ligand-receptor complex. As a template, the cocrystal structure of RgIA and RgIA[11r] in complex with the α7 (PDB: 7EKT) was utilized. The three-dimensional structures of RgIA were retrieved from the RCSB database (PDB: 2JUT). Subsequently, the native RgIA was subjected to RgIA[11r] using Schrödinger software(2020, New York, USA). The dimensions of the simulation box were set as ligand of template. The docking procedure utilized the standard precision (SP) method for docking precision and employed a flexible ligand sampling approach. Specifically, 50 poses per ligand were generated. To assess the binding affinity of each ligand, the docking score calculation was employed to determine the potency of each pose [35,36].

Conclusions
In this study, the D-type amino acid RgIA[11r] mutant of RgIA lost its inhibitory activity at the α9α10 nAChRs, but gained the ability to selectively target and inhibit both human and rat α7 nAChRs, while not inhibiting other subtypes of nAChRs. The pharmacological profile of RgIA[11r] renders it a promising molecular probe for studying α7 nAChRs, and it also demonstrates the potential for therapeutic applications. In addition, the findings from this study suggest that D-type amino acid substitution can modify not only peptide stability, but also peptide activity. Therefore, it represents an effective strategy for peptide modification, and has the potential to lead to the discovery of novel peptide-based therapeutics with improved properties.